144 related articles for article (PubMed ID: 17311764)
1. In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4).
Jin ZH; Razkin J; Josserand V; Boturyn D; Grichine A; Texier I; Favrot MC; Dumy P; Coll JL
Mol Imaging; 2007; 6(1):43-55. PubMed ID: 17311764
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4.
Jin ZH; Josserand V; Razkin J; Garanger E; Boturyn D; Favrot MC; Dumy P; Coll JL
Mol Imaging; 2006 Jul; 5(3):188-97. PubMed ID: 16954034
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive visualization and quantification of tumor αVβ3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4.
Jin ZH; Furukawa T; Galibert M; Boturyn D; Coll JL; Fukumura T; Saga T; Dumy P; Fujibayashi Y
Nucl Med Biol; 2011 May; 38(4):529-40. PubMed ID: 21531290
[TBL] [Abstract][Full Text] [Related]
4. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors.
Jin ZH; Josserand V; Foillard S; Boturyn D; Dumy P; Favrot MC; Coll JL
Mol Cancer; 2007 Jun; 6():41. PubMed ID: 17565663
[TBL] [Abstract][Full Text] [Related]
5. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide.
Sancey L; Lucie S; Garanger E; Elisabeth G; Foillard S; Stéphanie F; Schoehn G; Guy S; Hurbin A; Amandine H; Albiges-Rizo C; Corinne AR; Boturyn D; Didier B; Souchier C; Catherine S; Grichine A; Alexeï G; Dumy P; Pascal D; Coll JL; Jean-Luc C
Mol Ther; 2009 May; 17(5):837-43. PubMed ID: 19259068
[TBL] [Abstract][Full Text] [Related]
6. Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers.
Liu Z; Liu S; Niu G; Wang F; Liu S; Chen X
Mol Imaging; 2010 Feb; 9(1):21-9. PubMed ID: 20128995
[TBL] [Abstract][Full Text] [Related]
7. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts.
Chen X; Conti PS; Moats RA
Cancer Res; 2004 Nov; 64(21):8009-14. PubMed ID: 15520209
[TBL] [Abstract][Full Text] [Related]
8. Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.
Briat A; Wenk CH; Ahmadi M; Claron M; Boturyn D; Josserand V; Dumy P; Fagret D; Coll JL; Ghezzi C; Sancey L; Vuillez JP
Cancer Sci; 2012 Jun; 103(6):1105-10. PubMed ID: 22448775
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
10. Spectroscopically well-characterized RGD optical probe as a prerequisite for lifetime-gated tumor imaging.
Mathejczyk JE; Pauli J; Dullin C; Napp J; Tietze LF; Kessler H; Resch-Genger U; Alves F
Mol Imaging; 2011 Dec; 10(6):469-80. PubMed ID: 22201538
[TBL] [Abstract][Full Text] [Related]
11. αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4.
Jin ZH; Furukawa T; Degardin M; Sugyo A; Tsuji AB; Yamasaki T; Kawamura K; Fujibayashi Y; Zhang MR; Boturyn D; Dumy P; Saga T
Mol Cancer Ther; 2016 Sep; 15(9):2076-85. PubMed ID: 27422811
[TBL] [Abstract][Full Text] [Related]
12. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
[TBL] [Abstract][Full Text] [Related]
13. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice.
Jin ZH; Furukawa T; Ohya T; Degardin M; Sugyo A; Tsuji AB; Fujibayashi Y; Zhang MR; Higashi T; Boturyn D; Dumy P; Saga T
Nucl Med Commun; 2017 Apr; 38(4):347-355. PubMed ID: 28291159
[TBL] [Abstract][Full Text] [Related]
14. Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts.
Wang W; Ke S; Wu Q; Charnsangavej C; Gurfinkel M; Gelovani JG; Abbruzzese JL; Sevick-Muraca EM; Li C
Mol Imaging; 2004 Oct; 3(4):343-51. PubMed ID: 15802051
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alphavbeta3 integrin-targeted fluorochrome.
Waldeck J; Häger F; Höltke C; Lanckohr C; von Wallbrunn A; Torsello G; Heindel W; Theilmeier G; Schäfers M; Bremer C
J Nucl Med; 2008 Nov; 49(11):1845-51. PubMed ID: 18927332
[TBL] [Abstract][Full Text] [Related]
16. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
17. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
